25 XP   0   0   10

BeiGene Ltd
Buy, Hold or Sell?

Let's analyse Beigene together

PenkeI guess you are interested in BeiGene Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BeiGene Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BeiGene Ltd

I send you an email if I find something interesting about BeiGene Ltd.

Quick analysis of Beigene (30 sec.)










What can you expect buying and holding a share of Beigene? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.5%

What is your share worth?

Current worth
$34.20
Expected worth in 1 year
$26.43
How sure are you?
28.9%

+ What do you gain per year?

Total Gains per Share
$-7.77
Return On Investment
-5.4%

For what price can you sell your share?

Current Price per Share
$144.12
Expected price per share
$118.18 - $159.34
How sure are you?
50%

1. Valuation of Beigene (5 min.)




Live pricePrice per Share (EOD)

$144.12

Intrinsic Value Per Share

$-127.69 - $-146.37

Total Value Per Share

$-93.48 - $-112.17

2. Growth of Beigene (5 min.)




Is Beigene growing?

Current yearPrevious yearGrowGrow %
How rich?$3.5b$5b-$1.2b-32.3%

How much money is Beigene making?

Current yearPrevious yearGrowGrow %
Making money-$220.4m-$502.1m$281.7m127.8%
Net Profit Margin-43.1%-142.5%--

How much money comes from the company's main activities?

3. Financial Health of Beigene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#23 / 1010

Most Revenue
#27 / 1010

Most Profit
#1002 / 1010

Most Efficient
#525 / 1010

What can you expect buying and holding a share of Beigene? (5 min.)

Welcome investor! Beigene's management wants to use your money to grow the business. In return you get a share of Beigene.

What can you expect buying and holding a share of Beigene?

First you should know what it really means to hold a share of Beigene. And how you can make/lose money.

Speculation

The Price per Share of Beigene is $144.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Beigene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Beigene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $34.20. Based on the TTM, the Book Value Change Per Share is $-1.94 per quarter. Based on the YOY, the Book Value Change Per Share is $-4.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Beigene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.52-2.4%-2.20-1.5%-4.81-3.3%-3.30-2.3%-2.05-1.4%
Usd Book Value Change Per Share-0.99-0.7%-1.94-1.3%-4.45-3.1%0.870.6%0.910.6%
Usd Dividend Per Share0.000.0%0.000.0%0.830.6%0.220.2%0.120.1%
Usd Total Gains Per Share-0.99-0.7%-1.94-1.3%-3.63-2.5%1.090.8%1.030.7%
Usd Price Per Share180.36-188.52-176.30-209.25-137.43-
Price to Earnings Ratio-12.81--4.37--9.48--5.38--9.01-
Price-to-Total Gains Ratio-182.84--123.59--57.06--62.60--57.57-
Price to Book Ratio5.27-5.18-3.70-7.04-7.55-
Price-to-Total Gains Ratio-182.84--123.59--57.06--62.60--57.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share144.12
Number of shares6
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.22
Usd Book Value Change Per Share-1.940.87
Usd Total Gains Per Share-1.941.09
Gains per Quarter (6 shares)-11.666.54
Gains per Year (6 shares)-46.6426.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-47-5752116
20-93-104114242
30-140-151166368
40-187-198218494
50-233-24526104120
60-280-29232125146
70-327-33937146172
80-373-38642167198
90-420-43348188224
100-466-48053209250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%3.035.00.07.9%3.036.00.07.7%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%11.025.02.028.9%11.026.02.028.2%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.016.020.0%4.00.034.010.5%4.00.035.010.3%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%11.025.02.028.9%11.026.02.028.2%

Fundamentals of Beigene

About BeiGene Ltd

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Fundamental data was last updated by Penke on 2024-04-11 02:11:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BeiGene Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Beigene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Beigene to the Biotechnology industry mean.
  • A Net Profit Margin of -57.9% means that $-0.58 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BeiGene Ltd:

  • The MRQ is -57.9%. The company is making a huge loss. -2
  • The TTM is -43.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-57.9%TTM-43.1%-14.9%
TTM-43.1%YOY-142.5%+99.4%
TTM-43.1%5Y-261.0%+217.9%
5Y-261.0%10Y-96,151.8%+95,890.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-57.9%-200.1%+142.2%
TTM-43.1%-216.8%+173.7%
YOY-142.5%-288.3%+145.8%
5Y-261.0%-449.1%+188.1%
10Y-96,151.8%-605.5%-95,546.3%
1.1.2. Return on Assets

Shows how efficient Beigene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Beigene to the Biotechnology industry mean.
  • -6.3% Return on Assets means that Beigene generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BeiGene Ltd:

  • The MRQ is -6.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.3%TTM-3.7%-2.6%
TTM-3.7%YOY-7.1%+3.4%
TTM-3.7%5Y-7.6%+3.8%
5Y-7.6%10Y-10.5%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.3%-13.3%+7.0%
TTM-3.7%-12.8%+9.1%
YOY-7.1%-11.7%+4.6%
5Y-7.6%-13.9%+6.3%
10Y-10.5%-15.7%+5.2%
1.1.3. Return on Equity

Shows how efficient Beigene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Beigene to the Biotechnology industry mean.
  • -10.4% Return on Equity means Beigene generated $-0.10 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BeiGene Ltd:

  • The MRQ is -10.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.4%TTM-5.8%-4.6%
TTM-5.8%YOY-10.1%+4.3%
TTM-5.8%5Y-11.2%+5.5%
5Y-11.2%10Y-11.3%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.4%-16.9%+6.5%
TTM-5.8%-16.1%+10.3%
YOY-10.1%-15.1%+5.0%
5Y-11.2%-19.3%+8.1%
10Y-11.3%-20.2%+8.9%

1.2. Operating Efficiency of BeiGene Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Beigene is operating .

  • Measures how much profit Beigene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Beigene to the Biotechnology industry mean.
  • An Operating Margin of -60.5% means the company generated $-0.60  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BeiGene Ltd:

  • The MRQ is -60.5%. The company is operating very inefficient. -2
  • The TTM is -55.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-60.5%TTM-55.3%-5.2%
TTM-55.3%YOY-127.4%+72.1%
TTM-55.3%5Y-261.4%+206.1%
5Y-261.4%10Y-93,144.7%+92,883.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-60.5%-296.2%+235.7%
TTM-55.3%-232.5%+177.2%
YOY-127.4%-298.2%+170.8%
5Y-261.4%-492.1%+230.7%
10Y-93,144.7%-632.4%-92,512.3%
1.2.2. Operating Ratio

Measures how efficient Beigene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.60 means that the operating costs are $1.60 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BeiGene Ltd:

  • The MRQ is 1.605. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.307. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.605TTM1.307+0.298
TTM1.307YOY2.274-0.967
TTM1.3075Y3.612-2.305
5Y3.61210Y932.400-928.788
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6053.231-1.626
TTM1.3073.310-2.003
YOY2.2743.890-1.616
5Y3.6125.739-2.127
10Y932.4007.876+924.524

1.3. Liquidity of BeiGene Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Beigene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.32 means the company has $2.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BeiGene Ltd:

  • The MRQ is 2.322. The company is able to pay all its short-term debts. +1
  • The TTM is 3.091. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.322TTM3.091-0.769
TTM3.091YOY4.572-1.482
TTM3.0915Y5.017-1.926
5Y5.01710Y6.074-1.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3223.890-1.568
TTM3.0914.173-1.082
YOY4.5725.344-0.772
5Y5.0176.126-1.109
10Y6.0746.448-0.374
1.3.2. Quick Ratio

Measures if Beigene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Beigene to the Biotechnology industry mean.
  • A Quick Ratio of 1.98 means the company can pay off $1.98 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BeiGene Ltd:

  • The MRQ is 1.980. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.796. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.980TTM2.796-0.816
TTM2.796YOY5.193-2.397
TTM2.7965Y6.513-3.717
5Y6.51310Y8.724-2.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9803.514-1.534
TTM2.7963.998-1.202
YOY5.1935.380-0.187
5Y6.5136.105+0.408
10Y8.7246.404+2.320

1.4. Solvency of BeiGene Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Beigene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Beigene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.38 means that Beigene assets are financed with 38.5% credit (debt) and the remaining percentage (100% - 38.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BeiGene Ltd:

  • The MRQ is 0.385. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.336. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.385TTM0.336+0.049
TTM0.336YOY0.292+0.044
TTM0.3365Y0.312+0.024
5Y0.31210Y0.431-0.119
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3850.339+0.046
TTM0.3360.3360.000
YOY0.2920.271+0.021
5Y0.3120.366-0.054
10Y0.4310.389+0.042
1.4.2. Debt to Equity Ratio

Measures if Beigene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Beigene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 63.1% means that company has $0.63 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BeiGene Ltd:

  • The MRQ is 0.631. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.510. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.631TTM0.510+0.121
TTM0.510YOY0.414+0.097
TTM0.5105Y0.459+0.051
5Y0.45910Y0.437+0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6310.388+0.243
TTM0.5100.402+0.108
YOY0.4140.335+0.079
5Y0.4590.426+0.033
10Y0.4370.461-0.024

2. Market Valuation of BeiGene Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Beigene generates.

  • Above 15 is considered overpriced but always compare Beigene to the Biotechnology industry mean.
  • A PE ratio of -12.81 means the investor is paying $-12.81 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BeiGene Ltd:

  • The EOD is -10.237. Based on the earnings, the company is expensive. -2
  • The MRQ is -12.811. Based on the earnings, the company is expensive. -2
  • The TTM is -4.371. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.237MRQ-12.811+2.574
MRQ-12.811TTM-4.371-8.439
TTM-4.371YOY-9.485+5.113
TTM-4.3715Y-5.384+1.013
5Y-5.38410Y-9.006+3.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.237-2.264-7.973
MRQ-12.811-2.629-10.182
TTM-4.371-2.680-1.691
YOY-9.485-4.145-5.340
5Y-5.384-6.257+0.873
10Y-9.006-6.254-2.752
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BeiGene Ltd:

  • The EOD is -9.684. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.119. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.494. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.684MRQ-12.119+2.435
MRQ-12.119TTM-12.494+0.375
TTM-12.494YOY-10.121-2.373
TTM-12.4945Y-7.607-4.886
5Y-7.60710Y-15.832+8.225
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.684-2.973-6.711
MRQ-12.119-3.333-8.786
TTM-12.494-3.553-8.941
YOY-10.121-5.605-4.516
5Y-7.607-8.376+0.769
10Y-15.832-8.865-6.967
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Beigene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.27 means the investor is paying $5.27 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BeiGene Ltd:

  • The EOD is 4.214. Based on the equity, the company is fair priced.
  • The MRQ is 5.274. Based on the equity, the company is overpriced. -1
  • The TTM is 5.178. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.214MRQ5.274-1.060
MRQ5.274TTM5.178+0.096
TTM5.178YOY3.700+1.478
TTM5.1785Y7.043-1.866
5Y7.04310Y7.552-0.509
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.2141.896+2.318
MRQ5.2742.115+3.159
TTM5.1782.093+3.085
YOY3.7002.884+0.816
5Y7.0433.542+3.501
10Y7.5523.916+3.636
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BeiGene Ltd.

3.1. Institutions holding BeiGene Ltd

Institutions are holding 48.169% of the shares of BeiGene Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP10.128421.689510568897-1100000-9.4268
2023-12-31Capital Research & Mgmt Co - Division 36.07280.256163368722853974.7162
2023-12-31Hillhouse Capital Advisors, Ltd.4.961118.8154517690600
2023-12-31PRIMECAP Management Company4.78070.71234988639-20100-0.4013
2023-12-31Baillie Gifford & Co Limited.3.70530.55263866449-5149-0.133
2023-12-31Temasek Holdings Ltd.2.88853.0429301417100
2023-12-31T. Rowe Price Associates, Inc.1.82870.046219081891586249.0665
2023-12-31FMR Inc1.64960.02391721303-631427-26.8381
2023-12-31BlackRock Inc0.81920.0039854876491826.1043
2023-12-31Capital International Inc /ca/0.7762.2769809749-39482-4.6491
2023-12-31Boxer Capital LLC0.47924.494750000000
2023-12-31Amvescap Plc.0.45610.0204475885-1011299-68.0009
2023-12-31Goldman Sachs Group Inc0.41080.0069428678350797450.4269
2023-12-31Artal Group S A0.38762.42524044805460.1352
2023-12-31PUBLIC INVESTMENT FUND0.33960.181435438500
2023-12-31First Trust Advisors L.P.0.21060.04332197412197410
2023-12-31Bank of America Corp0.1690.0032176392-3726-2.0686
2023-12-31Capital International Sarl0.1691.1912176337107926.5191
2023-12-31M&G INVESTMENT MANAGEMENT LTD0.1660.110417326673254.4142
2023-12-31Baird Financial Group, Inc.0.15810.06781649333448126.4319
Total 40.556355.964242320148-1694298-4.0%

3.2. Funds holding BeiGene Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31American Funds New Perspective A2.38470.35422488364450001.8417
2023-12-31Capital Group New Perspective Comp2.38470.35422488364450001.8417
2023-12-31Vanguard PRIMECAP Inv2.18070.58122275590-1800-0.079
2024-02-29AF High Growth (AFRIS)1.73260.0233180800418080040
2023-12-31American Funds New World A1.060.373110605017027618.1963
2023-12-31Vanguard Capital Opportunity Inv0.9870.8847102993100
2023-12-31American Funds Europacific Growth A0.96650.1341008580322663.3049
2023-12-31Capital Group EuroPacific Growth Comp0.96650.1341008580322663.3049
2024-02-29Global Balanced (AFRIS)0.79480.05128294168294160
2023-12-31PRIMECAP Odyssey Aggressive Growth0.67691.772770638700
2023-12-31PRIMECAP Odyssey Growth0.64341.7681671427-8400-1.2356
2024-01-31Fidelity Growth Compy Commingled Pl O0.61940.1336646372111401.7537
2023-12-31T. Rowe Price Health Sciences0.55310.7076577168163812.9211
2024-02-29iShares Biotechnology ETF0.50181.1404523631-2355-0.4477
2024-01-31Fidelity Growth Company Fund0.45660.1288476449-4525-0.9408
2023-12-31T. Rowe Price International Growth Eq0.44060.56334597969840027.2278
2023-12-31T. Rowe Price International Stock0.44060.5674597969840027.2278
2023-12-31T. Rowe Price International Gr Eq Tr-D0.34690.55943620128360130.0279
2024-01-31Baillie Gifford WW L/T Glb Gr B USD Acc0.33171.386834614423110.6721
Total 18.468511.617519272061+3255381+16.9%

3.3. Insider Transactions

Insiders are holding 19.845% of the shares of BeiGene Ltd.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-12John OylerSELL37668164.02
2024-02-29Julia Aijun WangSELL397167.08
2023-07-31Chan Henry LeeSELL791216.26
2023-07-03Julia Aijun WangSELL472179.55
2023-06-26Lai WangSELL1108181.92
2023-06-26Xiaobin WuSELL1495182.37
2023-06-23Corazon (corsee) D. SandersSELL578182.32
2023-06-23Julia Aijun WangSELL840182.85
2023-06-20Lai WangSELL1325192.42
2023-06-14Advisors Ltd. HhlrSELL273728207.72
2023-06-12Advisors Ltd. HhlrSELL1250212195.21
2023-06-08Advisors Ltd. HhlrSELL1163825218.14
2023-06-07Lai WangSELL462224.74
2023-06-07Xiaobin WuSELL3291224.73
2023-05-08Xiaobin WuSELL7000253.72

4. Summary

4.1. Key Performance Indicators

The key performance indicators of BeiGene Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.986-1.944+97%-4.452+351%0.870-213%0.909-208%
Book Value Per Share--34.20136.376-6%48.422-29%34.3000%20.377+68%
Current Ratio--2.3223.091-25%4.572-49%5.017-54%6.074-62%
Debt To Asset Ratio--0.3850.336+15%0.292+32%0.312+24%0.431-11%
Debt To Equity Ratio--0.6310.510+24%0.414+53%0.459+38%0.437+44%
Dividend Per Share----0%0.825-100%0.220-100%0.116-100%
Eps---3.520-2.199-38%-4.809+37%-3.297-6%-2.045-42%
Free Cash Flow Per Share---3.721-4.182+12%-4.706+26%-3.7090%-2.180-41%
Free Cash Flow To Equity Per Share---0.397-3.181+700%-4.751+1096%0.755-153%0.854-147%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---146.373--------
Intrinsic Value_10Y_min---127.685--------
Intrinsic Value_1Y_max---16.686--------
Intrinsic Value_1Y_min---16.391--------
Intrinsic Value_3Y_max---48.597--------
Intrinsic Value_3Y_min---46.426--------
Intrinsic Value_5Y_max---78.653--------
Intrinsic Value_5Y_min---73.136--------
Market Cap15050163360.000-25%18834634080.00019808711596.735-5%18410917470.000+2%21875948007.347-14%14364211473.341+31%
Net Profit Margin---0.579-0.431-26%-1.425+146%-2.610+350%-961.518+165861%
Operating Margin---0.605-0.553-9%-1.274+111%-2.614+332%-931.447+153867%
Operating Ratio--1.6051.307+23%2.274-29%3.612-56%932.400-100%
Pb Ratio4.214-25%5.2745.178+2%3.700+43%7.043-25%7.552-30%
Pe Ratio-10.237+20%-12.811-4.371-66%-9.485-26%-5.384-58%-9.006-30%
Price Per Share144.120-25%180.360188.515-4%176.303+2%209.249-14%137.428+31%
Price To Free Cash Flow Ratio-9.684+20%-12.119-12.494+3%-10.121-16%-7.607-37%-15.832+31%
Price To Total Gains Ratio-146.104+20%-182.843-123.592-32%-57.057-69%-62.596-66%-57.574-69%
Quick Ratio--1.9802.796-29%5.193-62%6.513-70%8.724-77%
Return On Assets---0.063-0.037-41%-0.071+12%-0.076+19%-0.105+65%
Return On Equity---0.104-0.058-44%-0.101-3%-0.112+8%-0.113+9%
Total Gains Per Share---0.986-1.944+97%-3.627+268%1.090-190%1.025-196%
Usd Book Value--3571531000.0003822657500.000-7%5056642500.000-29%3586673100.0000%2130494315.789+68%
Usd Book Value Change Per Share---0.986-1.944+97%-4.452+351%0.870-213%0.909-208%
Usd Book Value Per Share--34.20136.376-6%48.422-29%34.3000%20.377+68%
Usd Dividend Per Share----0%0.825-100%0.220-100%0.116-100%
Usd Eps---3.520-2.199-38%-4.809+37%-3.297-6%-2.045-42%
Usd Free Cash Flow---388549000.000-438428500.000+13%-491429500.000+26%-387719050.0000%-227848684.211-41%
Usd Free Cash Flow Per Share---3.721-4.182+12%-4.706+26%-3.7090%-2.180-41%
Usd Free Cash Flow To Equity Per Share---0.397-3.181+700%-4.751+1096%0.755-153%0.854-147%
Usd Market Cap15050163360.000-25%18834634080.00019808711596.735-5%18410917470.000+2%21875948007.347-14%14364211473.341+31%
Usd Price Per Share144.120-25%180.360188.515-4%176.303+2%209.249-14%137.428+31%
Usd Profit---367553000.000-220427000.000-40%-502153500.000+37%-342460500.000-7%-205418763.158-44%
Usd Revenue--634409000.000614694750.000+3%353980250.000+79%289403450.000+119%167880052.632+278%
Usd Total Gains Per Share---0.986-1.944+97%-3.627+268%1.090-190%1.025-196%
 EOD+3 -5MRQTTM+12 -21YOY+22 -135Y+10 -2510Y+15 -20

4.2. Fundamental Score

Let's check the fundamental score of BeiGene Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.237
Price to Book Ratio (EOD)Between0-14.214
Net Profit Margin (MRQ)Greater than0-0.579
Operating Margin (MRQ)Greater than0-0.605
Quick Ratio (MRQ)Greater than11.980
Current Ratio (MRQ)Greater than12.322
Debt to Asset Ratio (MRQ)Less than10.385
Debt to Equity Ratio (MRQ)Less than10.631
Return on Equity (MRQ)Greater than0.15-0.104
Return on Assets (MRQ)Greater than0.05-0.063
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of BeiGene Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose143.450
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets5,805,275
Total Liabilities2,233,744
Total Stockholder Equity3,537,327
 As reported
Total Liabilities 2,233,744
Total Stockholder Equity+ 3,537,327
Total Assets = 5,805,275

Assets

Total Assets5,805,275
Total Current Assets4,203,414
Long-term Assets1,601,861
Total Current Assets
Cash And Cash Equivalents 3,183,273
Short-term Investments 2,600
Net Receivables 395,886
Inventory 416,122
Other Current Assets 205,533
Total Current Assets  (as reported)4,203,414
Total Current Assets  (calculated)4,203,414
+/-0
Long-term Assets
Property Plant Equipment 1,419,361
Long Term Investments 89,644
Intangible Assets 108,855
Other Assets 0
Long-term Assets  (as reported)1,601,861
Long-term Assets  (calculated)1,617,860
+/- 15,999

Liabilities & Shareholders' Equity

Total Current Liabilities1,810,113
Long-term Liabilities423,631
Total Stockholder Equity3,537,327
Total Current Liabilities
Short-term Debt 710,316
Short Long Term Debt 688,366
Accounts payable 315,111
Other Current Liabilities 761,735
Total Current Liabilities  (as reported)1,810,113
Total Current Liabilities  (calculated)2,475,528
+/- 665,415
Long-term Liabilities
Long term Debt 197,618
Capital Lease Obligations 44,201
Long-term Liabilities Other 170,846
Long-term Liabilities  (as reported)423,631
Long-term Liabilities  (calculated)412,665
+/- 10,966
Total Stockholder Equity
Common Stock135
Retained Earnings -7,962,050
Accumulated Other Comprehensive Income -99,446
Other Stockholders Equity 11,598,688
Total Stockholder Equity (as reported)3,537,327
Total Stockholder Equity (calculated)3,537,327
+/-0
Other
Capital Stock135
Cash and Short Term Investments 3,185,873
Common Stock Shares Outstanding 104,077
Current Deferred Revenue22,951
Liabilities and Stockholders Equity 5,805,275
Net Debt -2,253,088
Net Invested Capital 4,423,311
Net Working Capital 2,393,301
Property Plant and Equipment Gross 1,639,122
Short Long Term Debt Total 930,185



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-31
> Total Assets 
11,798
0
53,621
0
136,965
135,608
116,764
265,228
251,230
235,425
405,813
376,729
473,975
1,049,059
1,046,479
1,708,927
1,653,856
2,408,627
2,249,684
2,172,232
2,150,318
1,881,070
1,612,289
4,067,212
3,903,290
5,566,390
5,600,757
5,821,004
5,524,116
5,286,334
8,645,949
8,021,388
7,378,207
6,726,013
6,379,290
5,956,775
5,728,736
5,524,879
5,805,275
5,805,2755,524,8795,728,7365,956,7756,379,2906,726,0137,378,2078,021,3888,645,9495,286,3345,524,1165,821,0045,600,7575,566,3903,903,2904,067,2121,612,2891,881,0702,150,3182,172,2322,249,6842,408,6271,653,8561,708,9271,046,4791,049,059473,975376,729405,813235,425251,230265,228116,764135,608136,965053,621011,798
   > Total Current Assets 
4,434
0
47,188
0
130,200
128,211
106,269
251,782
232,754
209,953
374,399
336,178
418,691
962,330
913,497
1,585,702
1,516,707
2,180,195
1,943,842
1,796,730
1,755,680
1,435,550
1,172,696
3,595,187
3,392,404
4,965,736
4,960,690
5,140,979
4,799,039
4,432,835
7,613,880
6,948,139
6,345,876
5,749,168
4,713,456
4,704,318
4,401,419
4,053,542
4,203,414
4,203,4144,053,5424,401,4194,704,3184,713,4565,749,1686,345,8766,948,1397,613,8804,432,8354,799,0395,140,9794,960,6904,965,7363,392,4043,595,1871,172,6961,435,5501,755,6801,796,7301,943,8422,180,1951,516,7071,585,702913,497962,330418,691336,178374,399209,953232,754251,782106,269128,211130,200047,18804,434
       Cash And Cash Equivalents 
3,926
0
13,898
0
25,156
27,450
17,869
208,506
58,084
85,532
87,514
97,750
261,006
208,510
239,602
490,634
438,420
643,485
712,937
764,492
918,948
856,151
618,011
1,957,101
1,345,014
1,464,470
1,381,950
1,901,819
1,776,448
1,383,310
4,375,678
4,347,162
4,531,137
4,197,132
3,869,564
3,538,644
3,410,368
3,067,336
3,183,273
3,183,2733,067,3363,410,3683,538,6443,869,5644,197,1324,531,1374,347,1624,375,6781,383,3101,776,4481,901,8191,381,9501,464,4701,345,0141,957,101618,011856,151918,948764,492712,937643,485438,420490,634239,602208,510261,00697,75087,51485,53258,084208,50617,86927,45025,156013,89803,926
       Short-term Investments 
30,000
0
30,497
0
101,509
93,894
82,617
38,720
168,535
118,086
280,660
229,726
146,424
548,925
597,914
973,381
931,208
1,390,276
1,068,509
849,167
618,803
375,768
364,728
1,417,097
1,807,744
3,254,300
3,268,725
2,910,472
2,605,452
2,533,617
2,241,962
1,897,783
1,172,554
871,998
665,251
294,057
105,693
106,989
2,600
2,600106,989105,693294,057665,251871,9981,172,5541,897,7832,241,9622,533,6172,605,4522,910,4723,268,7253,254,3001,807,7441,417,097364,728375,768618,803849,1671,068,5091,390,276931,208973,381597,914548,925146,424229,726280,660118,086168,53538,72082,61793,894101,509030,497030,000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
872
0
0
181,471
29,428
49,970
47,664
45,041
52,764
67,670
61,478
57,636
72,810
77,975
82,690
87,657
79,673
103,928
118,456
163,563
500,175
216,348
192,279
202,645
173,168
332,158
338,140
354,618
395,886
395,886354,618338,140332,158173,168202,645192,279216,348500,175163,563118,456103,92879,67387,65782,69077,97572,81057,63661,47867,67052,76445,04147,66449,97029,428181,471008720000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,712
10,930
7,498
6,322
19,699
16,242
13,140
49,048
37,512
28,553
28,775
33,234
35,525
89,293
72,974
117,587
150,979
242,626
245,628
262,210
290,911
282,346
296,995
321,333
316,929
416,122
416,122316,929321,333296,995282,346290,911262,210245,628242,626150,979117,58772,97489,29335,52533,23428,77528,55337,51249,04813,14016,24219,6996,3227,49810,9305,7120000000000000
   > Long-term Assets 
0
0
6,433
0
6,765
7,397
10,495
13,446
18,476
25,472
31,414
40,551
55,284
86,729
132,982
123,225
137,149
228,432
305,842
375,502
394,638
445,520
439,593
472,025
510,886
600,654
640,067
680,025
725,077
853,499
1,032,069
1,073,249
1,032,331
976,845
845,946
1,252,457
1,327,317
1,471,337
1,601,861
1,601,8611,471,3371,327,3171,252,457845,946976,8451,032,3311,073,2491,032,069853,499725,077680,025640,067600,654510,886472,025439,593445,520394,638375,502305,842228,432137,149123,225132,98286,72955,28440,55131,41425,47218,47613,44610,4957,3976,76506,43300
       Property Plant Equipment 
7,052
0
5,931
0
6,234
6,541
6,612
7,702
9,752
16,554
25,977
30,723
33,770
55,322
62,568
87,660
96,816
122,265
194,235
306,274
320,723
338,267
313,127
378,224
405,442
443,204
446,298
509,131
538,487
609,768
686,744
624,673
633,100
829,881
845,946
1,053,558
1,144,500
1,289,123
1,419,361
1,419,3611,289,1231,144,5001,053,558845,946829,881633,100624,673686,744609,768538,487509,131446,298443,204405,442378,224313,127338,267320,723306,274194,235122,26596,81687,66062,56855,32233,77030,72325,97716,5549,7527,7026,6126,5416,23405,93107,052
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,984
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
0
0
001091091091091091091091091091091091091091091091091091091091091091091091,9840000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,964
26,241
36,756
49,344
55,711
53,951
87,428
100,792
83,890
87,587
96,080
91,779
97,947
95,607
89,281
89,644
89,64489,28195,60797,94791,77996,08087,58783,890100,79287,42853,95155,71149,34436,75626,24111,96400000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
19,688
19,715
19,925
19,007
18,928
52,230
6,841
6,509
6,178
52,811
5,563
5,375
5,188
53,731
4,813
12,008
14,104
103,348
45,807
43,325
40,849
94,568
39,735
46,895
53,657
108,855
108,85553,65746,89539,73594,56840,84943,32545,807103,34814,10412,0084,81353,7315,1885,3755,56352,8116,1786,5096,84152,23018,92819,00719,92519,71519,6880000000000000
       Long-term Assets Other 
0
0
502
0
531
856
3,883
5,744
8,724
8,918
4,669
6,900
16,687
2,051
42,915
14,210
11,452
52,751
13,232
8,991
9,161
30,401
2,476
38,228
33,918
67,388
24,623
32,046
40,771
35,246
30,652
203,010
164,781
9,926
-186,456
61,108
1,513
8,952
33,007
33,0078,9521,51361,108-186,4569,926164,781203,01030,65235,24640,77132,04624,62367,38833,91838,2282,47630,4019,1618,99113,23252,75111,45214,21042,9152,05116,6876,9004,6698,9188,7245,7443,883856531050200
> Total Liabilities 
48,757
0
27,853
0
27,052
35,531
116,764
22,129
31,183
47,593
405,813
68,312
203,803
284,570
362,248
350,205
427,188
425,196
496,037
549,553
579,054
586,833
633,934
1,240,156
1,356,798
1,269,876
1,731,514
1,817,417
1,917,341
1,929,261
2,402,962
2,135,888
2,075,663
2,070,842
1,995,935
1,799,469
1,930,177
1,761,645
2,233,744
2,233,7441,761,6451,930,1771,799,4691,995,9352,070,8422,075,6632,135,8882,402,9621,929,2611,917,3411,817,4171,731,5141,269,8761,356,7981,240,156633,934586,833579,054549,553496,037425,196427,188350,205362,248284,570203,80368,312405,81347,59331,18322,129116,76435,53127,052027,853048,757
   > Total Current Liabilities 
31,734
0
13,371
0
26,114
28,317
35,172
15,826
20,465
29,316
35,058
49,985
49,952
103,161
149,988
141,896
186,435
188,424
246,452
238,809
271,679
265,734
286,044
451,797
365,094
645,721
1,075,199
1,112,542
1,242,314
1,304,435
1,599,555
1,376,306
1,398,409
1,411,311
1,018,020
1,254,551
1,405,109
1,283,297
1,810,113
1,810,1131,283,2971,405,1091,254,5511,018,0201,411,3111,398,4091,376,3061,599,5551,304,4351,242,3141,112,5421,075,199645,721365,094451,797286,044265,734271,679238,809246,452188,424186,435141,896149,988103,16149,95249,98535,05829,31620,46515,82635,17228,31726,114013,371031,734
       Short-term Debt 
35,977
0
322
0
14,049
14,323
14,598
33
11,000
18,030
17,284
2,470
152,728
9,018
9,222
9,565
9,067
8,736
8,727
18,391
17,907
11,371
10,814
25,895
38,949
63,502
348,910
419,038
451,352
461,016
449,490
430,281
405,517
465,615
353,010
306,353
444,560
351,807
710,316
710,316351,807444,560306,353353,010465,615405,517430,281449,490461,016451,352419,038348,91063,50238,94925,89510,81411,37117,90718,3918,7278,7369,0679,5659,2229,018152,7282,47017,28418,03011,0003314,59814,32314,0490322035,977
       Short Long Term Debt 
35,977
0
13,838
0
0
0
14,598
6,000
11,000
18,030
17,284
2,470
152,728
9,018
9,222
9,565
9,067
8,736
8,727
8,940
8,740
700
0
11,298
26,061
50,222
335,015
405,045
434,802
442,372
427,565
407,387
380,729
441,275
328,969
281,808
421,052
328,561
688,366
688,366328,561421,052281,808328,969441,275380,729407,387427,565442,372434,802405,045335,01550,22226,06111,29807008,7408,9408,7278,7369,0679,5659,2229,018152,7282,47017,28418,03011,0006,00014,59800013,838035,977
       Accounts payable 
2,063
0
2,794
0
4,072
4,301
8,980
3,823
6,071
7,307
11,957
20,482
24,419
35,168
69,779
52,719
85,878
85,552
113,283
105,320
148,536
112,282
122,488
98,364
157,173
146,265
231,957
146,923
168,826
206,203
262,400
236,915
234,355
252,071
294,781
241,360
266,975
341,857
315,111
315,111341,857266,975241,360294,781252,071234,355236,915262,400206,203168,826146,923231,957146,265157,17398,364122,488112,282148,536105,320113,28385,55285,87852,71969,77935,16824,41920,48211,9577,3076,0713,8238,9804,3014,07202,79402,063
       Other Current Liabilities 
17,545
0
1,349
0
1,848
4,928
10,524
11,577
14,394
22,009
23,101
24,463
25,533
49,843
58,754
65,601
76,188
77,431
106,302
97,594
95,429
124,482
153,908
128,672
136,704
147,387
127,808
474,930
558,531
564,590
479,962
341,083
427,571
548,641
114,342
521,361
534,540
589,333
761,735
761,735589,333534,540521,361114,342548,641427,571341,083479,962564,590558,531474,930127,808147,387136,704128,672153,908124,48295,42997,594106,30277,43176,18865,60158,75449,84325,53324,46323,10122,00914,39411,57710,5244,9281,84801,349017,545
   > Long-term Liabilities 
0
0
14,482
0
938
7,214
7,273
6,303
10,718
18,277
17,848
18,327
153,851
181,409
212,260
208,309
240,753
236,772
249,585
310,744
307,375
321,099
347,890
788,359
991,704
624,155
656,315
704,875
675,027
624,826
803,407
759,582
677,254
659,531
977,915
544,918
525,068
478,348
423,631
423,631478,348525,068544,918977,915659,531677,254759,582803,407624,826675,027704,875656,315624,155991,704788,359347,890321,099307,375310,744249,585236,772240,753208,309212,260181,409153,85118,32717,84818,27710,7186,3037,2737,214938014,48200
       Long term Debt Total 
0
0
0
0
0
0
0
6,214
10,553
18,030
17,284
17,434
17,701
9,018
9,222
9,565
51,467
40,824
40,785
77,480
238,810
254,991
240,695
239,191
131,491
151,551
183,637
193,017
194,856
200,906
202,113
201,605
185,207
208,058
0
0
0
0
0
00000208,058185,207201,605202,113200,906194,856193,017183,637151,551131,491239,191240,695254,991238,81077,48040,78540,82451,4679,5659,2229,01817,70117,43417,28418,03010,5536,2140000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,996
27,829
29,518
36,647
47,564
44,053
41,959
43,312
40,558
50,722
56,257
64,966
62,883
66,709
61,244
58,558
57,088
49,329
48,720
44,201
44,20148,72049,32957,08858,55861,24466,70962,88364,96656,25750,72240,55843,31241,95944,05347,56436,64729,51827,82928,9960000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
89
165
247
564
893
136,150
141,055
178,230
198,744
189,286
195,948
197,661
221,931
191
169
171
460,699
425,064
460,720
461,886
501,064
303,302
410,654
269,629
543,758
219,498
436,224
179,784
207,244
209,032
191,986
170,846
170,846191,986209,032207,244179,784436,224219,498543,758269,629410,654303,302501,064461,886460,720425,064460,699171169191221,931197,661195,948189,286198,744178,230141,055136,150893564247165890000000
       Deferred Long Term Liability 
0
0
798
0
0
0
980
0
0
0
0
0
0
31,336
24,808
0
0
0
11,139
11,333
11,802
10,681
10,532
10,368
11,379
11,884
10,792
10,794
12,270
13,266
14,169
14,219
14,739
15,249
0
0
0
0
0
0000015,24914,73914,21914,16913,26612,27010,79410,79211,88411,37910,36810,53210,68111,80211,33311,13900024,80831,33600000098000079800
> Total Stockholder Equity
-38,726
0
25,768
0
109,913
100,077
-101,765
243,099
220,047
187,832
352,907
308,417
255,753
750,140
684,231
1,344,381
1,213,197
1,983,431
1,753,647
1,608,769
1,571,264
1,278,478
978,355
2,812,214
2,546,492
4,287,494
3,869,243
4,003,587
3,606,775
3,357,073
6,242,987
5,885,500
5,302,544
4,655,171
4,383,355
4,157,306
3,798,559
3,763,234
3,537,327
3,537,3273,763,2343,798,5594,157,3064,383,3554,655,1715,302,5445,885,5006,242,9873,357,0733,606,7754,003,5873,869,2434,287,4942,546,4922,812,214978,3551,278,4781,571,2641,608,7691,753,6471,983,4311,213,1971,344,381684,231750,140255,753308,417352,907187,832220,047243,099-101,765100,077109,913025,7680-38,726
   Common Stock
9
0
23
0
31
32
12
43
43
43
52
52
52
59
59
70
70
77
77
78
78
78
79
101
102
118
118
119
120
121
133
133
134
135
135
136
137
135
135
1351351371361351351341331331211201191181181021017978787877777070595952525243434312323102309
   Retained Earnings -7,962,050-7,594,497-7,809,910-7,428,773-7,080,342-6,635,007-5,971,826-5,400,377-4,966,103-4,380,450-3,966,595-3,486,254-3,552,749-3,080,004-2,654,780-2,319,578-1,955,843-1,567,782-1,260,425-1,174,855-1,007,215-738,960-594,929-438,042-330,517-231,194-348,580-288,035-237,412-199,814-164,320-140,195-118,195-90,945-76,9460-61,0930-42,815
   Capital Surplus 
0
0
0
0
0
0
0
384,502
385,787
388,568
591,213
597,268
604,603
981,237
1,000,747
1,782,033
1,804,942
2,710,053
2,744,814
2,777,474
2,814,449
2,861,012
2,925,970
5,138,239
5,200,275
7,367,799
7,414,932
7,486,518
7,561,155
7,724,822
11,191,007
11,268,290
11,356,686
11,451,566
0
0
0
0
0
0000011,451,56611,356,68611,268,29011,191,0077,724,8227,561,1557,486,5187,414,9327,367,7995,200,2755,138,2392,925,9702,861,0122,814,4492,777,4742,744,8142,710,0531,804,9421,782,0331,000,747981,237604,603597,268591,213388,568385,787384,5020000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
309
0
86,738
0
187,230
192,123
-157,857
384,502
385,787
388,568
591,213
597,268
604,603
981,237
1,000,747
1,782,033
1,804,942
2,710,053
2,744,814
2,777,474
2,814,449
2,861,012
2,925,970
5,138,239
5,200,275
7,367,799
7,414,932
7,486,518
7,561,155
7,724,822
11,191,007
11,268,290
11,356,686
11,451,566
11,540,979
11,644,957
11,607,249
11,502,527
11,598,688
11,598,68811,502,52711,607,24911,644,95711,540,97911,451,56611,356,68611,268,29011,191,0077,724,8227,561,1557,486,5187,414,9327,367,7995,200,2755,138,2392,925,9702,861,0122,814,4492,777,4742,744,8142,710,0531,804,9421,782,0331,000,747981,237604,603597,268591,213388,568385,787384,502-157,857192,123187,230086,7380309



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,458,779
Cost of Revenue-463,856
Gross Profit1,994,9231,994,923
 
Operating Income (+$)
Gross Profit1,994,923
Operating Expense-3,202,659
Operating Income-1,207,736-1,207,736
 
Operating Expense (+$)
Research Development1,698,158
Selling General Administrative1,416,938
Selling And Marketing Expenses0
Operating Expense3,202,6593,115,096
 
Net Interest Income (+$)
Interest Income0
Interest Expense-37,371
Other Finance Cost-113,325
Net Interest Income75,954
 
Pretax Income (+$)
Operating Income-1,207,736
Net Interest Income75,954
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-825,836-1,589,636
EBIT - interestExpense = -1,245,107
-825,836
-844,337
Interest Expense37,371
Earnings Before Interest and Taxes (EBIT)-1,207,736-788,465
Earnings Before Interest and Taxes (EBITDA)-1,120,061
 
After tax Income (+$)
Income Before Tax-825,836
Tax Provision-53,461
Net Income From Continuing Ops-959,490-879,297
Net Income-881,708
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,666,515
Total Other Income/Expenses Net381,900-75,954
 

Technical Analysis of Beigene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Beigene. The general trend of Beigene is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Beigene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BeiGene Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 141.34 < 157.39 < 159.34.

The bearish price targets are: 124.46 > 120.00 > 118.18.

Tweet this
BeiGene Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BeiGene Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BeiGene Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BeiGene Ltd.

BeiGene Ltd Daily Moving Average Convergence/Divergence (MACD) ChartBeiGene Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BeiGene Ltd. The current adx is .

BeiGene Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BeiGene Ltd.

BeiGene Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BeiGene Ltd.

BeiGene Ltd Daily Relative Strength Index (RSI) ChartBeiGene Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BeiGene Ltd.

BeiGene Ltd Daily Stochastic Oscillator ChartBeiGene Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BeiGene Ltd.

BeiGene Ltd Daily Commodity Channel Index (CCI) ChartBeiGene Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BeiGene Ltd.

BeiGene Ltd Daily Chande Momentum Oscillator (CMO) ChartBeiGene Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BeiGene Ltd.

BeiGene Ltd Daily Williams %R ChartBeiGene Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BeiGene Ltd.

BeiGene Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BeiGene Ltd.

BeiGene Ltd Daily Average True Range (ATR) ChartBeiGene Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BeiGene Ltd.

BeiGene Ltd Daily On-Balance Volume (OBV) ChartBeiGene Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BeiGene Ltd.

BeiGene Ltd Daily Money Flow Index (MFI) ChartBeiGene Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BeiGene Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

BeiGene Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BeiGene Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose143.450
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Beigene with someone you think should read this too:
  • Are you bullish or bearish on Beigene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Beigene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BeiGene Ltd

I send you an email if I find something interesting about BeiGene Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about BeiGene Ltd.

Receive notifications about BeiGene Ltd in your mailbox!